Founded in 2012 by Dr Peter Molloy and Dr Stephen Goodall, after nearly 10 years of development and testing, Firebrick Pharma’s first product – Nasodine® Nasal Spray – is now in the final stages of development.
Nasodine Nasal Spray contains the broad-spectrum antimicrobial agent, povidone-iodine. In clinical studies, Nasodine has been shown to be well-tolerated as a four-times-daily nasal spray. Patents have been filed worldwide on its use as a treatment and preventative for the common cold.
If approved, Nasodine will be a first-in-class nasal spray medicine that targets the cause of colds where they start, in the nose.
It is anticipated that FRE will list on the ASX during January 2022.
Home – Firebrick Pharma
Firebrick Pharma Pty Ltd is an Australian private company, founded in 2012 by two experienced pharmaceutical and biotech executives.
www.firebrickpharma.com
Be the first to comment